Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Financial Info
: Financials

Financials

v3.8.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 29,310 $ 18,941
Marketable securities-available for sale, at fair value 7,180
Prepaid expenses and other 896 1,019
Total current assets 30,206 27,140
Property and equipment, net 102 150
Restricted cash 89 89
Intangible asset 120 120
Security deposits 18 11
Total assets 30,535 27,510
Current liabilities:    
Accounts payable 1,362 872
Accrued expenses 475 1,244
Total current liabilities 1,837 2,116
Deferred rent payable 18 33
Total liabilities 1,855 2,149
Commitments (See Note 8)
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.001 par value; 150,000,000 and 15,000,000 shares authorized; 7,581,700 and 3,919,181 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively, 2,496 shares to be issued as of December 31, 2016 8 4
Additional paid in capital 185,552 166,604
Accumulated deficit (156,870) (141,240)
Accumulated other comprehensive loss (10) (7)
Total stockholders' equity 28,680 25,361
Total liabilities and stockholders' equity $ 30,535 $ 27,510
v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
COSTS AND EXPENSES:        
Research and development $ 3,908 $ 5,466 $ 9,708 $ 23,653
General and administrative 1,927 2,143 6,040 7,806
Total costs and expenses 5,835 7,609 15,748 31,459
Operating loss (5,835) (7,609) (15,748) (31,459)
Interest income, net 49 31 118 99
NET LOSS $ (5,786) $ (7,578) $ (15,630) $ (31,360)
Net loss per common share, basic and diluted (in dollars per share) $ (0.77) $ (2.90) $ (2.49) $ (14.52)
Weighted average common shares outstanding, basic and diluted (in shares) 7,508,036 2,613,109 6,287,062 2,160,157
v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (15,630) $ (31,360)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of premium on marketable securities 6 62
Depreciation of property and equipment 50 101
Stock-based compensation 1,477 2,367
Changes in operating assets and liabilities:    
Prepaid expenses 123 867
Security deposit (7)
Accounts payable 490 (2,114)
Accrued expenses and deferred rent (710) (1,795)
Net cash used in operating activities (14,201) (31,872)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (2) (66)
Proceeds from restricted cash 44
Maturities of marketable securities 7,174 12,715
Net cash provided by investing activities 7,172 12,693
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 14
Proceeds, net of expenses of $1,168 and $1,294, from sale of common stock 17,387 15,641
Net cash provided by financing activities 17,401 15,641
Effect of currency rate change on cash (3) 7
Net increase (decrease) in cash and cash equivalents 10,369 (3,531)
Cash and cash equivalents, beginning of the period 18,941 19,175
Cash and cash equivalents, end of period 29,310 15,644
Non-cash financing activities:    
Issuance of common stock under employee benefit plan $ 74 $ 167